Tolerability, safety and efficacy of iloprost infusion without peristaltic pump in systemic sclerosis;Tollerabilità, sicurezza ed efficacia del trattamento infusivo con iloprost senza pompa peristaltica in pazienti affetti da sclerosi sistemica

Reumatismo

Volumn 53, Issue 2, 2001, Pages 140-144

  Arreghini, M ^a   Prudente, P ^a   Maglione, W ^a   Arnoldi, C ^a   Tosi, S ^a   Marchesoni, A ^a  

^a ISTITUTO ORTOPEDICO GAETANO PINI   (Italy)

Author keywords

Iloprost; Raynaud's phenomenon; Scleroderma

Indexed keywords

ILOPROST;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DAY HOSPITAL; DISEASE DURATION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPOTENSION; NAUSEA; PERISTALTIC PUMP; RASH; RAYNAUD PHENOMENON; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME; VOMITING;

EID: 0034936554     PISSN: 00487449     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Pharmacokinetics and tolerability of oral iloprost in thromboangiitis obliterans patients
2. Treatment of patients with peripheral arterial occlusive disease Fontaine stage III and IV with intravenous iloprost: An open study in 900 patients
3. Placebo controlled study showing therapeutic benefit of iloprost in the treatment of Raynaud's phenomenon
4. Intravenous Iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study
5. Long-term iloprost infusion therapy for severe pulmonary hypertension in patients with connective tissue diseases
6. Inhibition of platelet aggregation by a new stable prostacyclin introduced in therapy of patients with progressive scleroderma
7. Iloprost effects on phagocytes in patients suffering from ischemic diseases: In vivo evidence for down-regulation of alpha M beta 2 integrin
8. Pharmacological effects of iloprost (ZK 36 374), a stable prostacyclin analogue, in man
9. Vascular disease in progressive systemic sclerosis (scleroderma)
10. Morphologic changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud phenomenon
11. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis
12. Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee: Preliminary criteria for the classification of systemic sclerosis (scleroderma)
13. Effects of five-day versus one-day infusion of iloprost on the peripheral microcirculation in patients with systemic sclerosis